Advertisement
Journal of Biological Chemistry
Open access logo
Advanced SearchSave search
Abstract only| Volume 262, ISSUE 33, P15894-15899, November 25, 1987

Effects of tamoxifen and 4-hydroxytamoxifen on the pNR-1 and pNR-2 estrogen-regulated RNAs in human breast cancer cells.

Open AccessPublished:November 25, 1987DOI:https://doi.org/10.1016/S0021-9258(18)47673-9
Effects of tamoxifen and 4-hydroxytamoxifen on the pNR-1 and pNR-2 estrogen-regulated RNAs in human breast cancer cells.
Previous ArticleThe effect of 2,3-diphosphoglycerate on the tetramer-dimer equilibrium of carbon monoxide hemoglobin in dilute solution. Correlation between sedimentation and kinetic behavior.
Next ArticleSugar transport by the bacterial phosphotransferase system. The intrinsic fluorescence of enzyme I.
      This paper is only available as a PDF. To read, Please Download here.
      The estrogenic and antiestrogenic activities of tamoxifen and 4-hydroxytamoxifen have been measured on the expression of two estrogen-regulated RNAs (pNR-1 and pNR-2) in the MCF7 human breast cancer cell line cultured in phenol red-free medium. The two antiestrogens increased the level of the pNR-1 RNA to about 80% of the estradiol-induced level, and the induction by estradiol was not significantly antagonized by either antiestrogen. In contrast, the pNR-2 mRNA was only increased to about 10% of the estradiol-induced level, and its induction by estradiol was antagonized by both tamoxifen and 4-hydroxytamoxifen. Thus, the two RNAs respond in dramatically different ways to these antiestrogens. 4-Hydroxytamoxifen and estradiol have similar affinities for the estrogen receptor; however, the induction of both RNAs by 4-hydroxytamoxifen required a 10-fold higher concentration than estradiol for maximum agonist activity, and a 500-fold molar excess was required to antagonize the induction by estradiol. Tamoxifen has a 20-100-fold lower affinity than estradiol for the estrogen receptor. A 200-fold higher concentration was required for maximum agonist activity and a 10,000-fold molar excess to antagonize the induction by estradiol. These results emphasize the complexity of antiestrogen action in human breast cancer cells.

      REFERENCES

        • Auffray C.
        • Rougeon F.
        Eur. J. Biochem. 1980; 107: 303-314
        • Berthois Y.
        • Katzenellenbogen J.A.
        • Katzenellenbogen B.S.
        Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 2496-2500
        • Brown A.M.C.
        • Jeltsch J.M.
        • Roberts M.
        • Chambon P.
        Proc. Natl. Acad. Sci. U. S. A. 1984; 81: 6344-6348
        • Cuzick J.
        • Wang D.Y.
        • Bulbrook R.D.
        Lancet. 1986; i: 83-86
        • Darbre P.D.
        • Curtis S.
        • King R.J.B.
        Cancer Res. 1984; 44: 2790-2793
        • Engel L.W.
        • Young N.A.
        • Tralka T.S.
        • Lippman M.E.
        • O'Brien S.J.
        • Joyce M.J.
        Cancer Res. 1978; 38: 3352-3364
        • Furr B.J.A.
        • Jordan V.C.
        Pharmacol. Ther. 1984; 25: 127-205
        • Goldberg D.A.
        Proc. Natl. Acad. Sci. U. S. A. 1980; 77: 5794-5797
        • Horwitz K.B.
        • Koseki Y.
        • McGuire W.L.
        Endocrinology. 1978; 103: 1742-1751
        • Jakowlew S.B.
        • Breatnach R.
        • Jeltsch J-M.
        • Masiakowski P.
        • Chambon P.
        Nucleic Acids Res. 1984; 12: 2861-2878
        • Jordan V.C.
        • Lieberman M.E.
        Mol. Pharmacol. 1984; 26: 279-285
        • Keydar I.
        • Chen L.
        • Karby S.
        • Weiss F.R.
        • Delarea J.
        • Radu M.
        • Chaitcik S.
        • Brenner H.J.
        Eur. J. Cancer. 1979; 15: 659-670
        • Klein-Hitpass L.
        • Schorpp M.
        • Wagner U.
        • Ryffel G.U.
        Cell. 1986; 46: 1053-1061
        • Lieberman M.E.
        • Gorski J.
        • Jordan V.C.
        J. Biol. Chem. 1983; 258: 4741-4745
        • Lippman M.E.
        • Bolan G.
        Nature. 1975; 256: 592-595
        • Masiakowski P.
        • Breathnach R.
        • Bloch J.
        • Gannon F.
        • Krust A.
        • Chambon P.
        Nucleic Acids Res. 1982; 10: 7895-7903
        • May F.E.B.
        • Westley B.R.
        Cancer Res. 1986; 46: 6034-6040
        • Melton D.A.
        • Krieg P.A.
        • Rebagliati M.R.
        • Maniatis T.
        • Zinn K.
        • Green G.R.
        Nucleic Acids Res. 1984; 12: 7035-7056
        • Millar M.A.
        • Katzenellenbogen B.S.
        Cancer Res. 1983; 43: 3094-3105
        • Patterson J.S.
        • Furr B.
        • Wakeling A.
        • Battersby L.
        Breast Cancer Res. Treat. 1982; 2: 363-374
        • Reddell R.R.
        • Sutherland R.L.
        Eur. J. Cancer Clin. Oncol. 1984; 20: 1419-1424
        • Reddell R.R.
        • Murphy L.C.
        • Hall R.E.
        • Sutherland R.L.
        Cancer Res. 1985; 45: 1525-1531
        • Rochefort H.
        • Borgna J-L.
        Nature. 1981; 292: 257-259
        • Sheen Y.Y.
        • Simpson D.M.
        • Katzenellenbogen B.S.
        Endocrinology. 1985; 117: 561-564
        • Soule H.D.
        • Vasquez J.
        • Lang A.
        • Albert S.
        • Brennan M.A.
        J. Natl. Cancer Inst. 1973; 51: 1409-1413
        • Southern E.M.
        J. Mol. Biol. 1975; 98: 503-517
        • Sutherland R.L.
        • Murphy L.C.
        • Foo M.S.
        • Green M.D.
        • Whybourne A.M.
        Nature. 1980; 288: 273-275
        • Wakeling A.
        • Slater S.R.
        Revs. Endocrine-related Cancer. 1981; : 134-154
        • Westley B.R.
        • May F.E.B.
        Nucleic Acids Res. 1987; 15: 3773-3786
        • Westley B.
        • Rochefort H.
        Cell. 1980; 20: 353-362
        • Westley B.
        • May F.E.B.
        • Brown A.M.C.
        • Krust A.
        • Chambon P.
        • Lippman M.E.
        • Rochefort H.
        J. Biol. Chem. 1984; 259: 10030-10035

      Article Info

      Publication History

      Published online: November 25, 1987

      Identification

      DOI: https://doi.org/10.1016/S0021-9258(18)47673-9

      Copyright

      © 1987 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.

      User License

      Creative Commons Attribution (CC BY 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution (CC BY 4.0)

      Permitted

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article
      • Reuse portions or extracts from the article in other works
      • Sell or re-use for commercial purposes

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect

      ASBMB  ASBMB  ASBMB  ASBMB

      ISSN 0021-9258
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX